Analysis of T- and B-Cell Subpopulations in Patients With Primary Membranous Nephropathy
概览
- 阶段
- 不适用
- 干预措施
- Control Group 2 (Healthy Volunteers)
- 疾病 / 适应症
- Membranous Nephropathy
- 发起方
- Istanbul University
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Distribution of T- and B-cell subpopulations
- 状态
- 已完成
- 最后更新
- 2个月前
概览
简要总结
The aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary membranous nephropathy (MN). A search for disease-related circulating antibodies [anti-phospholipase A2 receptor antibody (anti-PLA2R) and anti-thrombospondin type 1 domain-containing 7A antibody (anti-THSD7A)] in patients' sera is also planned.
The main questions to answer are:
- What is the relationship of these cell populations and their distribution during follow-up with treatment, treatment responses, and relapses?
- What is the relationship of the cell populations with anti-PLA2R (or anti-THSD7A) antibody levels?
Participants will provide peripheral venous blood samples at pre-designated regular intervals.
The research team will compare results of the primary MN group with two control groups (IgA nephropathy and healthy volunteer groups) to see if the findings are specific for primary MN.
详细描述
Primary membranous nephropathy (MN), which is one of the most common causes of nephrotic syndrome in adults, is an autoimmune disease characterized with remissions and exacerbations. About half of the patients who do not go into remission progress to end-stage kidney disease. In recent years, a lot of progress has been made in the fields of nephrology and immunology regarding primary MN. The process, which began with the detection of autoantibodies against the M-type phospholipase A2 receptor (PLA2R) in approximately 70% of the patients, continued with the discovery of new molecules for diagnosis and follow-up. However, despite all these advances, studies based on the analysis of peripheral blood mononuclear cells in patients with primary MN are very few: Rosenzwajg et al. analyzed lymphocyte subgroups in 25 MN patients and 27 healthy controls, and showed that regulatory T cells were significantly decreased in patients, naive B cells were increased, and memory B cells were decreased (Rosenzwajg et al. Kidney Int 2017). In 2020, Cantarelli et al. performed an extensive analysis in 30 patients with MN, showing that regulator B cells were increased in the MN group (Cantarelli et al. Kidney Int Rep 2020). These studies were generally cross-sectional or sampling was performed at a maximum of 6 months of follow-up. More studies based on long-term follow-up are needed. Therefore, the aim of this observational study is to provide analysis of T and B lymphocyte subgroups in peripheral blood samples of patients with primary MN. A search for disease-related circulating antibodies \[anti-phospholipase A2 receptor antibody (anti-PLA2R) and anti-thrombospondin type 1 domain-containing 7A antibody (anti-THSD7A)\] in patients' sera is also planned. It is designed to investigate the relationship of these cell populations and their distribution during follow-up with treatment, treatment responses, and relapses. The relationship of cell populations with antibody levels over time will also be examined. By investigating the distribution of T and B lymphocyte subgroups in patients with primary MN during the follow-up, and its relationship with treatment, treatment responses, and relapses, it is expected to better elucidate the pathogenesis of the disease and to detect cell changes suggestive of remission and recurrence.
研究者
Safak Mirioglu
Principal Investigator
Istanbul University
入排标准
入选标准
- •Having a diagnosis of primary membranous nephropathy (patient group).
- •Having a diagnosis of primary IgA nephropathy (diseased control group).
- •Being healthy (healthy control group).
- •Agreeing to participate in the research (informed consent).
排除标准
- •Refusing to participate in the research.
研究组 & 干预措施
Control Group 2 (Healthy Volunteers)
After the patient group sampling is completed, a healthy control group will be formed from healthy volunteers according to the distribution of age and sex (n=14). Samples will be collected from healthy volunteers for one time only (cross-sectional sampling).
Study Group (Primary Membranous Nephropathy)
Patients with biopsy-proven primary membranous nephropathy will be included (n=18). Samples will be collected from patients diagnosed with primary MN before starting conventional immunosuppressive therapy with calcineurin inhibitors (CNI) and corticosteroids (CS) and at 3, 6, 12, 18 and 24 months after starting the treatment. In case of failure after treatment with CNIs and CS treatment, rituximab (RTX) is used. If patient switches to RTX, samples will be taken before and 1, 3, 6, 12, 18, and 24 months after the first dose of RTX. If relapse occurs, sampling will be done regardless of the timing. Treatment decisions will solely be made in line with the guidelines, and there will be no intervention.
Control Group 1 (IgA Nephropathy)
After the patient group sampling is completed, a diseased control group will be formed from patients with primary IgA nephropathy according to the distribution of age and sex (n=12). Samples will be collected from the patients for one time only (cross-sectional sampling).
结局指标
主要结局
Distribution of T- and B-cell subpopulations
时间窗: 2 years
Distribution of T- and B-cell subpopulations will be evaluated with flow cytometry throughout the 2-year follow-up process.
次要结局
- Complete remission(2 years)
- Partial remission(2 years)
- Relapse(2 years)
- Composite kidney outcome(2 years)